p53 Function in Breast Cancer Progression

#p53 signaling in cancer progression and therapy:- •The p53 protein, a crucial transcription factor, is mutated in half of all human malignancies. Mutations disrupt the cell cycle, leading to uncontrolled cell proliferation and cancer. Mutant p53 proteins have oncogenic characteristics, affecting cancer cell proliferation, apoptosis, invasion, and metastasis. Due to its common prevalence in human cancer, p53 deficiency is a promising option for cancer treatment. •p53 and cancer progression:- The TP53 gene mutation is found in 50% of human cancers, affecting cell cycle and proliferation. Mutations in p53 proteins play a crucial role in cellular responses like DNA repair, cell cycle arrest, senescence, cell death, cell differentiation, and metabolism. Non-functional mutated p53 in tumor cells is associated with neoplastic diseases, including breast cancer. Mutant p53 proteins have oncogenic action in culture cells and promote metastasis and genomic instability in mice models. They can alter gene expression and interact with transcription factors, leading to spontaneous tumor development and cancer cell invasion. •Mutant p53 targets microRNAs, affecting their stability and influencing invasion and metastasis pathways. It increases invasive and metastatic activity in cancers like non-small lung cancer. It disrupts DNA repair mechanisms, modulates H-Ras, and regulates genomic stability. Mutant p53 and STAT signaling pathways are crucial in cancer development. •Mutant p53 and STAT signaling pathways are crucial in cancer development, affecting gene transcription, p53 response genes, and UV-induced cell growth arrest. Inhibiting STAT3 increases p53 expression, leading to tumor cell death. Mutant p53 can impair cell-mediated immunity, and targeting senescent cells through SASP regulation could be a new therapeutic path. •Cellular senescence and the secretory phenotype (SASP) in the elderly can cause illnesses. Targeting senescent cells through SASP regulation or cellular reprogramming could be a new therapeutic path for cancer and age-related illnesses. The TP53 gene, which regulates cellular senescence, apoptosis, and DNA repair, could be targeted by ELK1. Reactivating wild-type characteristics of p53 mutants, which are overexpressed in cancer, could be a viable therapeutic strategy. Small chemicals like Phi-Kan083 and PK7088 can bind to p53 and generate the Y220C mutant, potentially restoring anticancer drug chemosensitivity in cells harboring mutant p53 proteins. •Conclusion:- Understanding mutant p53 actions has identified compounds with therapeutic potential in cancer. However, more experiments are needed to fully characterize its function in cancer. Mutant p53 may promote metastasis, causing cancer-related mortality. Personalizing therapy based on specific mutations is crucial, rather than considering wild-type vs. mutant p53 expression.

A study reveals how mutations in the p53 protein can turn it from a tumor suppressor into a cancer driver by corrupting other proteins like p63 and p73. ⬇️ - Mutant p53 induces amyloid aggregation in p63 and p73 through an aberrant phase transition, leading to harmful protein clumps. 💡 Using advanced biophysical techniques and fluorescence microscopy, the team investigated three specific p53 mutations: M237I, commonly found in glioblastoma; R249S, which is prevalent in liver cancer; and R248Q, associated with breast cancer. They found that each of these mutants not only altered the behavior of p53 but also triggered p63 and p73 to form amyloid-like structures, further driving cancer progression. 💡 the research also revealed that heparin, a widely used anticoagulant, can inhibit the formation of these harmful aggregates. This suggests a potential therapeutic approach to prevent or reverse the malignancy-enhancing effects of mutant p53. ✅ The findings open new avenues for targeted cancer treatments to disrupt the harmful interactions caused by mutant p53. https://lnkd.in/e-ZKnqRV #cancer #cancerresearch #mutation #oncology #precisiononcology #p53 #targetedtherapy #tumorsuppressor #oncogene

Correcting TP53 nonsense mutations with circular ADAR-recruiting RNAs in LNPs Reading this on my commute yesterday, and really needed to make a quick post about it. The team introduced the use circular ADAR-recruiting RNA (or Circ-arRNA as they are referred in the paper) delivered via LNPs to correct TP53-W53X nonsense mutations in triple-negative breast cancer. This RNA editing approach overall seems to restore functional p53 protein, significantly boosting tumor sensitivity to Taxol (paclitaxel) chemotherapy with high precision and safety. What did they find? In just a few words: 1) High editing efficiency + enhanced stability: Circ-arRNA LNPs achieve 73.32% mutation correction in 4T1 cells and 48.48% in tumor-bearing mice, converting UAG stop codons to UIG (UGG) with no off-target effects. Regarding stability, circ-arRNA exhibits a ~8-day half-life, ~2 days longer than linear arRNA, ensuring sustained intracellular activity and 4.4-fold higher editing efficiency. Quite an enhancement let me say. 2) Restored p53 function + improved chemotherapy response: In vivo, Circ-arRNA LNPs restored full-length p53, upregulating BAX and cleaved caspase-3 while downregulating BCL-2, promoting tumor cell apoptosis. Combined with nab-paclitaxel, Circ-arRNA LNPs potently suppress tumor growth in mice, with no significant toxicity to liver, kidney, or heart. 3) Safe delivery: LNPs using FDA-approved D-Lin-MC3-DMA were able to ebsure effective cytosolic delivery and lysosomal escape, with 63.5% encapsulation efficiency and no adverse effects. Hey, cool paper right? Still, I think there are some limitations. For once, the study’s intratumoral delivery limits systemic application. Also, targeted LNP formulations for intravenous or oral administration are needed if this is to become a treatment. Besides, nonsense-mediated mRNA decay (NMD) effects were not assessed due to the model’s lack of splicing, requiring advanced models for further validation. Lastly, scaling production and optimizing for other nonsense mutations remain future goals. Wanna know more: https://lnkd.in/e-jQSGdn #RNAEditing #NonsenseMutations #TP53 #CircarRNA #LipidNanoparticles #BreastCancer #p53Restoration #Chemotherapy #PrecisionMedicine #ADAR